GlassScriptPhysician profile
Neal Breit
NPI 1558419630
$11,819.94
in general payments reported to CMS, 2019-2025
20 companies · $334 in 2025
The $334 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,266 · 2020: $1,700 · 2021: $1,097 · 2022: $377 · 2023: $337 · 2024: $1,709 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,200 · Food and Beverage: $1,030 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,200.00 |
| Food and Beverage | $1,030.13 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $5,589.75 | 2019 | |
| Ibsa Pharma INC. | $4,074.59 | 2019-2024 | Tirosint, Licart |
| Boehringer Ingelheim Pharmaceuticals, INC. | $543.75 | 2019-2024 | Jardiance |
| Amgen INC. | $531.25 | 2022-2025 | Evenity, Prolia |
| Novo Nordisk INC | $271.42 | 2019-2021 | |
| Lilly USA, LLC | $158.28 | 2019-2024 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $143.97 | 2019-2022 | |
| Mannkind Corporation | $98.44 | 2019-2020 | |
| Abbott Laboratories | $63.39 | 2019-2023 | Freestyle Libre 3 |
| Radius Health, INC. | $54.88 | 2019-2025 | Tymlos |
| Merck Sharp & Dohme LLC | $42.28 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $41.44 | 2021-2025 | Unithroid |
| Zealand Pharma US, INC. | $40.23 | 2021-2022 | |
| Kyowa Kirin, INC. | $31.75 | 2025 | |
| Sanofi-Aventis U.S. LLC | $26.53 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.38 | 2020 | |
| Antares Pharma, INC. | $25.36 | 2019 | |
| Medtronic Minimed, INC. | $21.66 | 2019 | |
| Dexcom, INC. | $18.47 | 2019 | |
| Beta Bionics, INC. | $17.12 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Neal Breit listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.